Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency

Explore clinical trials studying Primary Immunodeficiency. Study availability and eligibility vary by location and protocol.

28 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency trial results

Completed

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

NCT04566692

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Clinical Research Center of Alabama Birmingham, Alabama, United States
  • Research Solutions of Arizona, PC Litchfield Park, Arizona, United States
  • Allergy Associates of The Palm Beaches North Palm Beach, Florida, United States
  • Allergy & Asthma Clinics of Georgia, P.C. Albany, Georgia, United States
View Trial Details
Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

NCT04561115

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Alabama Allergy & Asthma Center Birmingham, Alabama, United States
  • Allergy Associates of the Palm Beaches PA North Palm Beach, Florida, United States
  • The South Bend Clinic Center for Research South Bend, Indiana, United States
  • Institute for Asthma and Allergy Chevy Chase, Maryland, United States
View Trial Details
Completed

What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?

NCT03815357

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, IRAK4 Deficiency, +7 more
Locations
  • Sydney Children's Hospital Sydney, New South Wales, Australia
  • Adelaide Women's and Children's Hospital Adelaide, South Australia, Australia
  • Monash Health Clayton, Victoria, Australia
  • Royal Children's Hospital Melbourne, Victoria, Australia
View Trial Details
Completed

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

NCT02269163

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California, Irvine Irvine, California, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Immunoe International Research Centennial, Colorado, United States
  • National Jewish Hospital Denver, Colorado, United States
View all 13 locations
View Trial Details
Completed

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593

Conditions
Agammaglobulinemia, Antibody Deficiency, Blood Protein Disorders, +11 more
Locations
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Family Allergy & Asthma Center, PC Atlanta, Georgia, United States
  • Rush University Chicago, Illinois, United States
View all 15 locations
View Trial Details
Completed

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

NCT03907241

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Octapharma Research Site Irvine, California, United States
  • Octapharma Research Site San Diego, California, United States
  • Octapharma Research Site Centennial, Colorado, United States
  • Octapharma Research Site Papillion, Nebraska, United States
View Trial Details
Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

NCT02806986

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Wesley Medical Research Auchenflower, Australia
  • Royal Melbourne Hospital Parkville, Australia
  • University Hospital Hradec Králové, Czechia
  • CHU de Montpellier Montpellier, France
View all 23 locations
View Trial Details

Related conditions